ZIVO Bioscience Inc. (ZIVO)
ZIVO Bioscience Statistics
Share Statistics
ZIVO Bioscience has 3.76M shares outstanding. The number of shares has increased by 35.34% in one year.
| Shares Outstanding | 3.76M |
| Shares Change (YoY) | 35.34% |
| Shares Change (QoQ) | 11.68% |
| Owned by Institutions (%) | 13.11% |
| Shares Floating | 1.34M |
| Failed to Deliver (FTD) Shares | 32 |
| FTD / Avg. Volume | 3.95% |
Short Selling Information
The latest short interest is 35.47K, so 1% of the outstanding shares have been sold short.
| Short Interest | 35.47K |
| Short % of Shares Out | 1% |
| Short % of Float | 2.72% |
| Short Ratio (days to cover) | 6.65 |
Valuation Ratios
The PE ratio is -5.48 and the forward PE ratio is -15.72. ZIVO Bioscience's PEG ratio is 0.37.
| PE Ratio | -5.48 |
| Forward PE | -15.72 |
| PS Ratio | 466.38 |
| Forward PS | 29.3 |
| PB Ratio | 48.02 |
| P/FCF Ratio | -17 |
| PEG Ratio | 0.37 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ZIVO Bioscience.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.8, with a Debt / Equity ratio of 0.17.
| Current Ratio | 0.8 |
| Quick Ratio | 0.8 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.06 |
| Interest Coverage | -582.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $22.46K |
| Profits Per Employee | $-1.91M |
| Employee Count | 7 |
| Asset Turnover | 0.1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 97.12% in the last 52 weeks. The beta is 0.11, so ZIVO Bioscience's price volatility has been higher than the market average.
| Beta | 0.11 |
| 52-Week Price Change | 97.12% |
| 50-Day Moving Average | 18.88 |
| 200-Day Moving Average | 15.94 |
| Relative Strength Index (RSI) | 33.36 |
| Average Volume (20 Days) | 810 |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of 157.22K and earned -13.38M in profits. Earnings per share was -3.92.
| Revenue | 157.22K |
| Gross Profit | 48.95K |
| Operating Income | -13.36M |
| Net Income | -13.38M |
| EBITDA | -13.36M |
| EBIT | -13.36M |
| Earnings Per Share (EPS) | -3.92 |
Balance Sheet
The company has 1.54M in cash and 254.36K in debt, giving a net cash position of 1.29M.
| Cash & Cash Equivalents | 1.54M |
| Total Debt | 254.36K |
| Net Cash | 1.29M |
| Retained Earnings | -136.97M |
| Total Assets | 1.64M |
| Working Capital | -406.38K |
Cash Flow
In the last 12 months, operating cash flow was -4.31M and capital expenditures 0, giving a free cash flow of -4.31M.
| Operating Cash Flow | -4.31M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.31M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 31.14%, with operating and profit margins of -8498.85% and -8513.44%.
| Gross Margin | 31.14% |
| Operating Margin | -8498.85% |
| Pretax Margin | -8513.44% |
| Profit Margin | -8513.44% |
| EBITDA Margin | -8498.85% |
| EBIT Margin | -8498.85% |
| FCF Margin | -2743.61% |
Dividends & Yields
ZIVO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ZIVO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 27, 2023. It was a backward split with a ratio of 1:6.
| Last Split Date | Oct 27, 2023 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -125.95 |
| Piotroski F-Score | 3 |